ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

DNAnexus and Intelliseq Combine Efforts to Add Automated Genomic Variant Interpretation and Clinical Reporting Capabilities to Precision Health Data Cloud

Integrated and Intuitive workflows designed to generate actionable insights into somatic cancers and hereditary diseases

DNAnexus, Inc., the provider of the Precision Health Data Cloud, and Intelliseq, a genome informatics company and innovative provider of next-generation sequencing (NGS) analysis solutions, today announced a partnership to simplify and accelerate variant interpretation and clinical reporting. As part of the agreement, DNAnexus is adding Intelliseq’s automated genome interpretation and reporting capabilities to its Precision Health Data Cloud. The integrated, one-click solution will streamline NGS data analysis and provide scientists with the ability to generate critical insights into somatic cancers, hereditary diseases, and other precision medicine and biomedical research applications.

The combined offering provides users with a complete analysis solution from NGS variant calling to final clinical interpretation, all on the secure and scalable DNAnexus Precision Health Data Cloud. Intelliseq’s iFlow™ Engine translates raw DNA sequences into complete reports with clinical insights. It fits all NGS analysis approaches from a single gene to whole genome. Users are able to take advantage of prebuilt workflows for somatic cancer and hereditary diseases using Intelliseq’s GeneSpect Reporters, or use Intelliseq’s Customica package for custom projects. The two companies will add Intelliseq’s GeneSpect Pharmacogenomics and Polygenic Risk Score Reporters in early 2024.

“DNAnexus has built the world’s most secure cloud platform and global network for scientific collaboration and accelerated discovery,” said Klaudia Szklarczyk-Smolana, CEO of Intelliseq. “The combination of our technologies will help unlock precision health datasets and enable researchers to transform how complex diseases are diagnosed, treated, and ultimately, prevented.”

Today, DNAnexus has more than 40,000 registered users across 48 countries. The company actively manages and supports more than 80 petabytes of complex clinical genomic, proteomic, and other multi-omic datasets on behalf of a growing network of collaborations with leading pharmaceutical, clinical diagnostic, academic research, biobank, and government organizations. The comprehensive cloud platform meets the most rigorous industry standards for data quality, security, privacy, and regulatory compliance.

“This partnership with Intelliseq is another example of how we are committed to continuously improving the user experience for our platform,” said Thomas Laur, CEO at DNAnexus. “Our customers can now take advantage of Intelliseq’s proven, best-in-class tertiary analysis tools on our Precision Health Data Cloud with just the click of a button.”

About Intelliseq

Intelliseq is a genome informatics company, focused on the development of novel algorithms and bioinformatics tools devoted to the interpretation of the human DNA sequence. Backed by a team of skilled scientists and bioinformatics experts, its state-of-the-art iFlow™ engine offers tailored solutions for researchers, clinicians, and biotech companies, enabling them to unlock the vast potential of genomic data in personalized medicine and disease research. The system drives lab efficiency through streamlined raw DNA data-to-reporting workflows in a variety of genome medicine applications.

For more information on Intelliseq, please visit www.intelliseq.com.

About DNAnexus

DNAnexus enables biomedical organizations to accelerate scientific discovery and improve patient care with the Precision Health Data Cloud. The company provides scientific innovators and healthcare professionals with the ability to manage, analyze, and collaborate on multi-omic, clinical and real-world data to unlock insights. DNAnexus actively manages more than 80 petabytes of data on behalf of a growing network of collaborations with leading pharmaceutical, clinical diagnostic, academic research, biobank, and government organizations. Today, more than 45,000 users across 48 countries and over 130 enterprise customers are harnessing the full potential of their data with the scalable and secure Precision Health Data Cloud. DNAnexus is headquartered in Mountain View, Calif. For more information, visit www.dnanexus.com or follow @DNAnexus.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.